Objective

2

To observe the effectiveness and safety of

Zhoufei Dingchuan Ointment

（皱肺定喘膏） combined with conventional western medicine in the treatment of stable chronic obstructive pulmonary disease （COPD） with lung-kidney deficiency pattern.

Methods

2

Sixty-five patients with stable COPD were randomly divided into two groups； 31 cases in the control group were treated with conventional western medicine， while 34 cases in the treatment group were additionally given

Zhoufei Dingchuan Ointment

， 20 g each time， once daily for 10 weeks. Both groups were followed up for one year since the initiation of medication， and the outcomes including the percentage of forced expiratory volume in the first second to the predicted value （FEV1%Pre）， the percentage of forced vital capacity to the predicted value （FVC%Pre）， the ratio of forced expiratory volume in the first second and the forced expiratory volume （FEV1/FVC） were assessed before treatment and after one year follow-up. The COPD assessment test （CAT） score， 6-minute walking distance （6MWD） and the frequency of acute exacerbation during follow-up were compared between groups， and the adverse reactions were recorded.

Results

2

Compared to those before treatment， 6MWD， FEV1%Pre and FEV1/FVC were significantly increased， and CAT score was reduced in the treatment group （

P

＜0.05 or

P

＜0.01）， while those outcomes were not significantly changed in the control group （

P

＞0.05）. After treatment， the levels of 6MWD， FEV1%pre， FVC%pre and FEV1/FVC in the treatment group were significantly higher than those in the control group （

P

＜0.05）， while the CAT score was significantly lower （

P

＜0.05）. There was no significant difference in the frequency of acute exacerbation between groups （

P

＞0.05）， and no significant drug-related adverse reactions were observed in both groups.

Conclusion

2

Compared to conventional western medicine alone， add-on

Zhoufei Dingchuan Ointment

can improve the lung function， enhance exercise endurance and improve the quality of life in stable COPD patients with lung-kidney pattern， and is safe.